Compare Enveric Biosciences Inc (ENVB) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Marqeta Inc — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Marqeta Inc trades at $17.78 (market cap $1.83B). The key difference: Marqeta Inc is far larger — about 344× Enveric Biosciences Inc's market cap, and Marqeta Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | MQ | |
|---|---|---|
Market Cap | $5.32M | $1.83B |
Sector | Health | Technology |
52-Week High | $17.40 | $27.32 |
52-Week Low | $1.28 | $15.04 |
Enterprise Value | $408.82K | $1.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Marqeta (MQ) trades at $17.63, up 9.3% in the last session, with a bullish technical outlook and a consensus price target of $19.00. The company reported mixed quarterly earnings, beating expectations in Q1 2026 but missing in Q4 2025. Revenue has stabilized around $625 million in 2025 after declines from 2022-2024, while net income remains negative. A 4:1 reverse stock split was effective July 1, 2026, to boost the share price. Operating cash flow improved significantly to $162.62 million in 2025.
The outlook is cautiously optimistic with analyst support but high valuation multiples pose risks. Investment opportunities include potential earnings growth and European expansion, while risks involve thin profit margins, competitive pressures, and ongoing profitability challenges. The stock's technical strength and positive sentiment may drive short-term gains, but fundamental improvements are needed for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
